# A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis

> **NCT03282318** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 119 (actual)

## Conditions studied

- Bladder Pain Syndrome
- Interstitial Cystitis

## Interventions

- **DRUG:** ASP6294
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03282318
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-28
- **Primary completion:** 2019-03-21
- **Final completion:** 2019-03-21
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03282318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03282318, "A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03282318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*